Issue link: https://beckershealthcare.uberflip.com/i/759246
13 SPINE LEADERSHIP The power of a unique process. OSTEOAMP does more than just provide the structural scaff old for bone growth. Its unique process delivers an allograft with the clinical benefi t of growth factors found in bone and bone marrow. OSTEOAMP provides essential elements supporting bone formation, backed by science, to meet the surgeon's need for a proven allograft that can achieve solid fusion outcomes. Learn more about OSTEOAMP and our full portfolio at BioventusSurgical.com OSTEOAMP maintains and preserves a wide array of naturally occurring growth factors found in bone and bone marrow at high levels to deliver clinical results (such as aFGF, BMP-2, BMP-7, TGF-ß1). 1-3 OSTEOAMP may be used in situations where an autograft is appropriate, such as spinal fusion procedure. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects. Please see OSTEOAMP instructions for use for complete list of contraindications, warnings, and precautions. 1. RPT-000327 Report on Growth Factor Concentrations in Bone and Bone Marrow Aspirate, December 3, 2010, Advanced Biologics, LLC. Data from a single lot of OSTEOAMP sponge product. 2. High levels relative to those reported in published literature for other allografts. 3. Bae H, Zhao L, Zhu D, Kanim L, Wang J, Delamarter R. Variability Across Ten Production Lots of a Single Demineralized Bone Matrix Product. J Bone Joint Surg Am. 2010; 92:427-35. © 2016 Bioventus LLC. I Bioventus, the Bioventus logo, and OSTEOAMP are registered trademarks of Bioventus LLC. I SMK-001880 I 09/16 The Art and Science of Orthobiologics. 12,000 10,000 8,000 6,000 4,000 2,000 0 CONCENTRATION (ng/g) αFGF BMP-2 BMP-7 TGF-β1 αFGF BMP-2 BMP-7 TGF-β1 Quantitative Analysis of Growth Factors in OSTEOAMP The Spine Industry & Where It's Headed — MACRA, Big Data & More By Megan Wood N orth Amer- ican Spine Society Past President Chris- topher Bono, MD, chief of spine service at Boston-based Brigham and Women's Hospital, shares what he's been witnessing in the spine industry and what the next few years will likely bring. 1. Surgery approval is becoming a hindrance. e approval and pre-authori- zation process for spine surgery continues to immensely burden spine surgeons. "It hasn't gotten better and it continues to get worse and worse for spine surgery, spine inter- ventions and spine injections," Dr. Bono says. "It's becoming also prohibitive [due to] the hoops that we have to jump through." 2. MACRA still causes much uncertain- ty. Causing a lot of anxiety among healthcare providers, the Medicare Access and CHIP Re- authorization Act of 2015's Quality Payment Program is set to commence Jan. 1 for the per- formance calendar year 2017. "What's giving a lot of spine surgeons a lot of unease is how it's going to affect day-to-day- practice," says Dr. Bono. Under MACRA, facilities will choose the Mer- it-based Incentive Payment System pathway or participate in the Advanced Alternative Pay- ment Models by 2017 or 2018. Dr. Bono thinks those choosing MIPS will not necessarily need to shi their algorithms much to comply. However, bundling will change everything for those centers going the APM route. Instead of negotiating for reimbursements, the payer will pay a lump sum of money for the episode of care. en, it will be up to the facility to decide how to disperse the money amongst the providers. "We won't be fighting with the insurance com- panies anymore; we will be fighting internally and with each other," says Dr. Bono. 3. Data analytics market is going strong. It's all about data, offering insight into complications and outcome predictions. e healthcare analytics market is expected to reach an $18.7 billion value by 2020, according to MarketsandMarkets report. "[e technology trend] is not necessarily new technology like intervention; it's really been on analysis of big data," Dr. Bono says. 4. Care delivery technology will en- hance risk stratification. e industry has witnessed a slowdown of new surgical tech- nology, opening the door for a "blossoming of care delivery technology." Currently, many patients are receiving proce- dures from which they will likely benefit, but many patients are undergoing surgeries from which they will not see improvement, thus creating poor outcomes. "With better analysis of big data, we are going to be able to risk stratify those patients much better," explains Dr. Bono. "It will take a lot of restraint and bravery when dealing with patients." e vignette of a patient undergoing a proce- dure because they want to, despite the high likelihood for unfavorable outcomes, is com- mon and only increases medical care costs. n Dr. Christopher Bono "What's giving a lot of spine surgeons a lot of unease is how [MACRA] is going to affect day-to-day practice." — Dr. Christopher Bono